Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0069 | Indomethacin

Molecular Formula C19H16ClNO4
Molecular Weight 357.8
Structure
State solid
Clearance In a clinical pharmacokinetic study, the plasma clearance of indometacin was reported to range from 1 to 2.5 mL/kg/min following oral administration.[A177874]
Volume of distribution The volume of distribution ranged from 0.34 to 1.57 L/kg following oral, intravenous, or rectal administration of single and multiple doses of indometacin in healthy individuals.[A177964] Indometacin is distributed into the synovial fluid [A177874] and is extensively bound to tissues [A177949]. It has been detected in human breast milk [A177874] and placenta.[L6778] Although indometacin has been shown to cross the blood-brain barrier (BBB)[L6778], its extensive plasma protein binding allows only the small fraction of free or unbound indometacin to diffuse across the BBB.[A177949]
Route of elimination Indometacin is eliminated via renal excretion, metabolism, and biliary excretion. It is also subject to enter the enterohepatic circulation through excretion of its glucuronide metabolites into bile followed by resorption of indometacin after hydrolysis [A177949]. The extent of involvement in the enterohepatic circulation ranges from 27 to 115%.[A177949] About 60 percent of an oral dosage is recovered in urine as drug and metabolites (26 percent as indomethacin and its glucuronide), and 33 percent in the feces (1.5 percent as indomethacin).[L6778]
Protein binding Indometacin is a weak organic acid that is 90-99% bound to protein in plasma over the expected range of therapeutic plasma concentrations [A177949,L6778]. Like other NSAIDs, indometacin is bound to plasma albumin [A177949] but it does not bind to red blood cells. [A177874]
Half life Indometacin disposition from the plasma is reported to be biphasic, with a half-life of 1 hour during the initial phase and 2.6–11.2 hours during the second phase.[A177949] Interindividual and intraindividual variations are possible due to the extensive and sporadic nature of the enterohepatic recycling and biliary discharge of the drug.[A177874,A177949] The mean half-life of oral indomethacin is estimated to be about 4.5 hours.[L6778] The disposition of intravenous indometacin in preterm neonates was shown to vary across premature infants. In neonates older than 7 days, the mean plasma half-life of intravenous indometacin was approximately 20 hours, ranging from 15 hours in infants weighing more than 1000 g and 21 hours in infants weighing less than 1000 g.[F4600]
Absorption Indometacin displays a linear pharmacokinetics profile where the plasma concentrations and area under the curve (AUC) are dose-proportional, whereas half-life (T1/2) and plasma and renal clearance are dose-dependent.[A177871] Indometacin is readily and rapidly absorbed from the gastrointestinal tract. The bioavailability is virtually 100% following oral administration [A177871] and about 90% of the dose is absorbed within 4 hours.[L6778] The bioavailability is about 80-90% following rectal administration.[A177901] The peak plasma concentrations following a single oral dose were achieved between 0.9 ± 0.4 and 1.5 ± 0.8 hours in a fasting state.[A177901] Despite large intersubject variation as well using the same preparation, peak plasma concentrations are dose-proportional and averaged 1.54 ± 0.76 μg/mL, 2.65 ± 1.03 μg/mL, and 4.92 ± 1.88 μg/mL following 25 mg, 50 mg, and 75 mg single doses in fasting subjects, respectively.[A177901] With a typical therapeutic regimen of 25 or 50 mg t.i.d., the steady-state plasma concentrations of indomethacin are an average 1.4 times those following the first dose.[L6778]
Trade names Indocid, Indocin
Description nonsteroidal anti-inflammatory drug (NSAID); anti-inflammatory, analgesic, and antipyretic; indole-acetic acid derivative; nonselective inhibition of cyclooxygenase (COX)

S

M

C

S01CC02 Indometacin and antiinfectives


[S01CC] Antiinflammatory agents, non-steroids and antiinfectives in combination


[S01C] ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION


[S01] OPHTHALMOLOGICALS


[S] Sensory organs

S01BC01 Indometacin


[S01BC] Antiinflammatory agents, non-steroids


[S01B] ANTIINFLAMMATORY AGENTS


[S01] OPHTHALMOLOGICALS


[S] Sensory organs

M02AA23 Indometacin


[M02AA] Antiinflammatory preparations, non-steroids for topical use


[M02A] TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN


[M02] TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN


[M] Musculoskeletal system

M01AB51 Indometacin, combinations


[M01AB] Acetic acid derivatives and related substances


[M01A] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS


[M01] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS


[M] Musculoskeletal system

M01AB01 Indometacin


[M01AB] Acetic acid derivatives and related substances


[M01A] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS


[M01] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS


[M] Musculoskeletal system

C01EB03 Indometacin


[C01EB] Other cardiac preparations


[C01E] OTHER CARDIAC PREPARATIONS


[C01] CARDIAC THERAPY


[C] Cardiovascular system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
UNCOUPLING rat isolated liver mitochondria increase 65
UNCOUPLING rat isolated liver mitochondria measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay Negative 53
UNCOUPLING 197
UNCOUPLING 197
UNCOUPLING rat heart 197
PROTONOPHORIC UNCOUPLING 278
MEMBRANE POTENTIAL 443.2 µM 30 mins mouse liver mitochondria Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) decrease EC20 36
RESPIRATION 25.2 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. decrease EC20 36
RESPIRATION ND 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. Negative EC20 36
ELECTRON TRANSPORT CHAIN rat isolated liver mitochondria decrease 65
ELECTRON TRANSPORT CHAIN rat isolated liver mitochondria measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay Negative 53
SWELLING > 800 µM 30 mins mouse liver mitochondria swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) increase EC20 36
MEGAMITOCHONDRIA 0.3-0.5 mM 22 h primary culture rat hep-atocytes, RL-34,COS-1, IAR-20 induce 292

Target Dose Time Species Model Method Action Positive criterion Reference
NADH:ubiquinone reductase 25.2 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. inhibit EC20 36
Succinate dehydrogenase ND 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. Negative EC20 36
Glycerol-3-phosphate dehydrogenase, mitochondrial inhibitor 162
Cytochrome c > 200 µM 30 mins mouse liver mitochondria Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) release EC20 36

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 159 companies from 19 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H300 (77.36%): Fatal if swallowed [Danger Acute toxicity, oral]


H301 (22.64%): Toxic if swallowed [Danger Acute toxicity, oral]


H317 (11.95%): May cause an allergic skin reaction [Warning Sensitization, Skin]


H318 (22.01%): Causes serious eye damage [Danger Serious eye damage/eye irritation]


H335 (22.01%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure


Respiratory tract irritation]


H336 (22.01%): May cause drowsiness or dizziness [Warning Specific target organ toxicity, single exposure


Narcotic effects]


H360 (12.58%): May damage fertility or the unborn child [Danger Reproductive toxicity]


H373 (22.01%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]


H413 (22.01%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P201, P202, P260, P261, P264, P270, P271, P272, P273, P280, P281, P301+P310, P302+P352, P304+P340, P305+P351+P338, P308+P313, P310, P312, P314, P321, P330, P333+P313, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Danger

H300: Fatal if swallowed [Danger Acute toxicity, oral]


 P264, P270, P301+P310, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 subcutaneous 18300ug/kg (18.3mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1398, 1980.
cat LDLo intravenous 20200ug/kg (20.2mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 726, 1983.
man TDLo rectal 2586mg/kg/3.5 (2586mg/kg) sense organs and special senses: "retinal changes (pigmentary depositions, retinitis, other): eye" American Journal of Ophthalmology. Vol. 73, Pg. 846, 1972.
human TDLo oral 113mg/kg/8W-I (113mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 33, Pg. 636, 1983.
man TDLo oral 714ug/kg (0.714mg/kg) Allergy. Vol. 54, Pg. 90, 1999.
man TDLo unreported 499mg/kg/87W- (499mg/kg) Arthritis and Rheumatism. Vol. 20, Pg. 917, 1977.
man TDLo oral 22500ug/kg/3W (22.5mg/kg) gastrointestinal: ulceration or bleeding from large intestine Annals of Pharmacotherpy. Vol. 29, Pg. 883, 1994.
mammal (species unspecified) LD50 oral 8mg/kg (8mg/kg) Indian Journal of Medical Research. Vol. 81, Pg. 621, 1985.
guinea pig LD50 oral 100mg/kg (100mg/kg) Oyo Yakuri. Pharmacometrics. Vol. 2, Pg. 70, 1968.
infant TDLo oral 400ug/kg/2D-I (0.4mg/kg) gastrointestinal: necrotic ghanges Journal of Pediatrics. Vol. 107, Pg. 484, 1985.
women TDLo oral 2098ug/kg/1D- (2.098mg/kg) Southern Medical Journal. Vol. 78, Pg. 1390, 1985.
rat LD50 oral 2420ug/kg (2.42mg/kg) gastrointestinal: ulceration or bleeding from stomach Arzneimittel-Forschung. Drug Research. Vol. 25, Pg. 1526, 1975.
rat LD50 intraperitoneal 13mg/kg (13mg/kg) Toxicology and Applied Pharmacology. Vol. 38, Pg. 127, 1976.
infant TDLo intravenous 200ug/kg (0.2mg/kg) blood: hemorrhage Journal of Pediatrics. Vol. 107, Pg. 312, 1985.
man LDLo oral 15mg/kg/2W-I (15mg/kg) blood: aplastic anemia Israel Journal of Medical Sciences. Vol. 17, Pg. 433, 1981.
man TDLo multiple routes 3557mg/kg/5Y- (3557mg/kg) sense organs and special senses: "retinal changes (pigmentary depositions, retinitis, other): eye" American Journal of Ophthalmology. Vol. 73, Pg. 846, 1972.
rat LD50 rectal 31900ug/kg (31.9mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 14, Pg. 2259, 1986.
dog LD50 oral 160mg/kg (160mg/kg) Oyo Yakuri. Pharmacometrics. Vol. 2, Pg. 70, 1968.
rat LD50 intravenous 21mg/kg (21mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 31, Pg. 655, 1981.
women TDLo oral 10mg/kg (10mg/kg) behavioral: coma Japanese Journal of Toxicology. Vol. 12, Pg. 337, 1999.
man TDLo oral 4286ug/kg/2D- (4.286mg/kg) skin and appendages (skin): "dermatitis, other: after systemic exposure" Postgraduate Medical Journal. Vol. 72, Pg. 186, 1996.
dog LD50 intravenous 100mg/kg (100mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1398, 1980.
rabbit LD50 oral 135mg/kg (135mg/kg) Drugs in Japan Vol. 6, Pg. 90, 1982.
mouse LD50 oral 11841ug/kg (11.841mg/kg) German Offenlegungsschrift Patent Document. Vol. #3005827,
guinea pig LD50 intraperitoneal 143mg/kg (143mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1398, 1980.
mouse LD50 intraperitoneal 10mg/kg (10mg/kg) Archivos de Farmacologia y Toxicologia. Vol. 8, Pg. 201, 1982.
rat LD50 subcutaneous 12mg/kg (12mg/kg) Oyo Yakuri. Pharmacometrics. Vol. 2, Pg. 70, 1968.
hamster LD50 oral 81mg/kg (81mg/kg) Archives of Toxicology, Supplement. Vol. 7, Pg. 365, 1984.
mouse LD50 intramuscular 18200ug/kg (18.2mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1398, 1980.
rat LD skin > 250mg/kg (250mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 14, Pg. 3185, 1986.
guinea pig LD50 intravenous 180mg/kg (180mg/kg) Journal de Pharmacologie. Vol. 2, Pg. 259, 1971.
rat LD50 intramuscular 26300ug/kg (26.3mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1398, 1980.
man TDLo oral 22500ug/kg/3W (22.5mg/kg) British Medical Journal. Vol. 3, Pg. 155, 1967.
guinea pig LD skin > 100mg/kg (100mg/kg) behavioral: excitement Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 14, Pg. 3185, 1986.
mouse LD50 intravenous 30mg/kg (30mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 1198, 1969.
cat LD50 oral 320mg/kg (320mg/kg) Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 1398, 1980.

  • Ankylosing spondylitis

  • Arthritis

  • Back pain

  • Bursitis

  • Colitis ulcerative

  • Drug interaction

  • Dysmenorrhoea

  • Fracture

  • Gouty arthritis

  • Inflammation

  • Joint dislocation

  • Ligament sprain

  • Multiple fractures

  • Musculoskeletal disorder

  • Oedema

  • Osteoarthritis

  • Patent ductus arteriosus

  • Periarthritis

  • Proctocolitis

  • Rheumatoid arthritis

  • Synovitis

  • Tendonitis

  • Tenosynovitis

  • Abdominal pain

  • Constipation

  • Decreased appetite

  • Dermatitis

  • Diarrhoea

  • Dizziness

  • Dyspepsia

  • Gastrointestinal pain

  • Headache

  • Hot flush

  • Hyperhidrosis

  • Loss of consciousness

  • Menopausal symptoms

  • Nausea

  • Post procedural haemorrhage

  • Post procedural oedema

  • Post procedural swelling

  • Presyncope

  • Pruritus

  • Pruritus generalised

  • Rash

  • Shock

  • Somnolence

  • Syncope

  • Vomiting

    • (1-p-Chlorobenzoyl-5-methoxy-2-methylindol-3-yl)acetic acid .alpha.-(1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl)acetic acid 1-(4-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid
    1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid & MAP-30 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid
    1-(4-chloro-benzoyl)-5-methoxy-2-methyl-3-indolyl-acetic acid 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid 1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure
    1-(p-Chlorbenzoyl)-5-methoxy-2-methylindol-3-essigsaeure [German] 1-(p-Chlorobenzoyl)-2-methoxy-3-methyl-1H-indole-3-acetic Acid 1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indole-acetic acid
    1-(p-Chlorobenzoyl)-2-methyl-5-methoxyindole-3-acetic acid 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindol-3-acetic acid 1-(p-Chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
    1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indoleacetic acid 1-(p-chlorobenzoyl)-2-methyl-5-methoxy-3-indolylacetic acid 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indol acetic acid
    1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolylacetic acid 1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico
    1-p-Cloro-benzoil-5-metoxi-2-metilindol-3-acido acetico [Spanish] 1-p-chlorobenzoyl-2-methyl-5-methoxyindol-3-acetic acid 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-
    1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9CI) 1z9h 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid
    2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]acetic acid 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid
    2-{1-((4-chlorophenyl)carbonyl)-5-methoxy-2-methylindol-3-yl}acetic acid 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2 methylindol-3-yl}acetic acid 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1h-indol-3-yl}acetic acid
    2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methylindol-3-yl}acetic acid 2-{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2methylindol-3-yl}acetic acid 4kyk
    5-22-05-00239 (Beilstein Handbook Reference) 53-86-1 74252-25-8
    87377-08-0 AB00052022 AB00052022-20
    AB00052022-21 AB00052022_23 AB00052022_24
    AB1009492 AC-532 ACT02579
    AKOS000592893 ANW-42683 ARONIS27005
    Aconip Aconip (TN) Amuno
    Arthrexin Artracin Artrinovo
    Artrivia BCP18951 BDBM17638
    BIDD:GT0132 BIM-0050670.0001 BP-30207
    BPBio1_000160 BRD-K57222227-001-06-1 BRD-K57222227-001-18-6
    BRD-K57222227-001-27-7 BRN 0497341 BSPBio_000144
    BSPBio_001149 BSPBio_002176 Bio2_000405
    Bio2_000885 Bonidin Bonidon
    Bonidon Gel C01926 CAS-53-86-1
    CCG-40186 CCRIS 3502 CGIGDMFJXJATDK-UHFFFAOYSA-
    CGIGDMFJXJATDK-UHFFFAOYSA-N CHEBI:49662 CHEMBL6
    CS-2242 CTK3J2195 Catlep
    Certified Reference Material Chibro-amuno Chrono-indicid
    Chrono-indocid Confortid D00141
    DB-052413 DB00328 DSSTox_CID_740
    DSSTox_GSID_20740 DSSTox_RID_75763 DTXSID9020740
    DivK1c_000271 Dolcidium Dolcidium PL
    Dolovin Durametacin EC 200-186-5
    EINECS 200-186-5 EU-0100692 Elmetacin
    FLAM FT-0603227 Flexin continus
    GTPL1909 H911 HMS1362I11
    HMS1568H06 HMS1792I11 HMS1920F21
    HMS1990I11 HMS2089N19 HMS2091N09
    HMS2095H06 HMS2231J10 HMS3262K05
    HMS3268A14 HMS3374F07 HMS3403I11
    HMS3414N13 HMS3430L03 HMS3649K17
    HMS3655O04 HMS3678N11 HMS3712H06
    HMS3747K21 HMS500N13 HSDB 3101
    HY-14397 Hicin I 7378
    I0655 IDI1_000271 IDI1_002160
    IMN Idomethine Imbrilon
    InChI=1/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) Inacid Indacin
    Indameth Indmethacine Indo-Lemmon
    Indo-Spray Indo-phlogont Indo-rectolmin
    Indo-tablinen Indochron E-R Indocid
    Indocid (pharmaceutical) Indocin Indocin (TN)
    Indocin Sr Indocin-SR Indocollyre
    Indolar SR Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- Indole-3-acetic acid, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl- (8CI)
    Indomecol Indomed Indomee
    Indomet 140 Indometacin (JP17/INN) Indometacin 1.0 mg/ml in Acetonitrile
    Indometacin [INN] Indometacina Indometacina [INN-Spanish]
    Indometacine Indometacine [INN-French] Indometacinum
    Indometacinum [INN-Latin] Indometacyna Indometacyna [Polish]
    Indomethacin & MAP-30 Indomethacin (Indocid, Indocin) Indomethacin (USP)
    Indomethacin [USAN:BAN] Indomethacin [USAN:USP] Indomethacin(Indocid)
    Indomethacin, >=99% (TLC) Indomethacin, >=99.0% (TLC) Indomethacin, Antibiotic for Culture Media Use Only
    Indomethacin, European Pharmacopoeia (EP) Reference Standard Indomethacin, Pharmaceutical Secondary Standard Indomethacin, United States Pharmacopeia (USP) Reference Standard
    Indomethacin, meets USP testing specifications Indomethacin,(S) Indomethacine
    Indomethacinum Indomethancin Indomethazine
    Indomethegan Indomethine Indometicina
    Indometicina [Spanish] Indomo Indomod
    Indonol Indoptic Indoptol
    Indorektal Indoxen Inflazon
    Infrocin Innamit Inteban
    Inteban sp J10170 KBio1_000271
    KBio2_000489 KBio2_001399 KBio2_003057
    KBio2_003967 KBio2_005625 KBio2_006535
    KBio3_000897 KBio3_000898 KBio3_001396
    KBioGR_000395 KBioGR_000489 KBioSS_000489
    KBioSS_001399 KS-00000WRK KS-000048I8
    KS-5255 KSC492C9L Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy
    Kwas 1-(p-chlorobenzoilo)-2-metylo-5-metoksy-3-indolilooctowy [Polish] L000959 LP00692
    LS-187 LS-82147 Lausit
    Lopac-I-7378 Lopac0_000692 MCULE-5636486088
    MFCD00057095 MLS000069402 MLS001074194
    MLS006011845 Metacen Metartril
    Methazine Metindol Mezolin
    Miametan Mikametan Mobilan
    MolMap_000032 N-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolylacetic acid N-p-Chlorbenzoyl-5-methoxy-2-methylindole-3-acetic acid
    NCGC00015562-01 NCGC00015562-02 NCGC00015562-03
    NCGC00015562-04 NCGC00015562-05 NCGC00015562-06
    NCGC00015562-07 NCGC00015562-08 NCGC00015562-09
    NCGC00015562-10 NCGC00015562-11 NCGC00015562-12
    NCGC00015562-13 NCGC00015562-14 NCGC00015562-15
    NCGC00015562-16 NCGC00015562-17 NCGC00015562-18
    NCGC00015562-19 NCGC00015562-20 NCGC00015562-21
    NCGC00015562-22 NCGC00015562-24 NCGC00015562-25
    NCGC00024135-02 NCGC00024135-04 NCGC00024135-05
    NCGC00024135-06 NCGC00024135-07 NCGC00024135-08
    NCGC00024135-09 NCGC00024135-10 NCGC00024135-11
    NCGC00024135-12 NCGC00024135-13 NCGC00024135-14
    NCGC00024135-15 NCGC00254075-01 NCGC00259340-01
    NCGC00261377-01 NCI-C56144 NCI60_041708
    NE11089 NINDS_000271 NSC-757061
    NSC757061 Opera_ID_56 Oprea1_686105
    Osmosin Pharmakon1600-01500350 Prestwick0_000272
    Prestwick1_000272 Prestwick2_000272 Prestwick3_000272
    Prestwick_597 PubChem17620 Q-201239
    Q409231 RTR-019032 Reumacide
    Rheumacin LA S00108 SBB057417
    SBI-0050670.P004 SC-17536 SCHEMBL9300
    SMR000058195 SPBio_000979 SPBio_002363
    SPECTRUM1500350 SR-01000000014 SR-01000000014-10
    SR-01000000014-16 SR-01000000014-2 SR-01000000014-4
    SR-01000000014-6 ST24039048 ST50320042
    STL257874 SW196768-5 Sadoreum
    Spectrum2_000970 Spectrum3_000468 Spectrum4_000018
    Spectrum5_000868 Spectrum_000919 TR-019032
    Tannex Tivorbex Tocris-1708
    Tox21_113109 Tox21_113109_1 Tox21_201791
    Tox21_300266 Tox21_500692 UNII-XXE1CET956
    UPCMLD-DP023 UPCMLD-DP023:001 Vonum
    XXE1CET956 Z56784896 ZINC601283
    [1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid [1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid # alpha-(1-(p-Chlorobenzoyl)-2-methyl-5-methoxy-3-indolyl)acetic acid
    indometacin indomethacin s1723
    {1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid

    DrugBank Name Indomethacin
    DrugBank DB00328
    CAS Number 28751-45-3, 36798-16-0, 53-86-1, 87377-08-0
    PubChem Compound 3715
    KEGG Compound ID C01926
    KEGG Drug D00141
    PubChem.Substance 46508291
    ChEBI 49662
    PharmGKB PA449982
    ChemSpider 3584
    BindingDB 17638.0
    TTD DAP000617
    Wikipedia Indomethacin
    HET IMN
    DPD 10126

    1. Dykens et al. (2007)
    2. Krause et al. (2003)
    3. Vuda et al. (2016)
    4. Ya?ez et al., 2003
    5. Chan et al. (2005)
    6. Moreno-Sanchez et al. (1999)